

Research Article**A PROSPECTIVE OBSERVATIONAL STUDY OF PLATELET RICH PLASMA AS MODALITY OF TREATMENT OF OSTEOARTHRITIS****Dr Rohit Madhup Lal^{1*}, Dr Sweta Lal²**

^{1*}MBBS, D.ORTHO, DNB(ORTHO), MNAMS(ORTHO) Fellow arthroscopic surgeries, SPORTS MED SA HOSPITAL, ADELAIDE, AUSTRALIA SENIOR CONSULTANT, Orthopaedic Surgery, Samford Hospital, Ranchi, Jharkhand, India.

²Associate Professor, Department of Obstetrics and Gynecology, SBMCH, Hazaribag.

Corresponding Author: Dr Rohit Madhup Lal

MBBS, D.ORTHO, DNB(ORTHO), MNAMS(ORTHO) Fellow arthroscopic surgeries, SPORTS MED SA HOSPITAL, ADELAIDE, AUSTRALIA SENIOR CONSULTANT, Orthopaedic Surgery, Samford Hospital, Ranchi, Jharkhand, India.

Received date: 05-07-2026, date of acceptance: 15-07-2026, Date of publication: 06-08-2026

Abstract

Introduction: Osteoarthritis is a degenerative, chronic disease that affects up to 80% of the population over 75 years of age. A recent report indicates that knee osteoarthritis is likely to become the fourth most crucial aetiology of physical limitation in women and the eighth most in men. In middle-aged persons, osteoarthritis may cause a major burden in lost time at work and early retirement. Non-modifiable risk factors for osteoarthritis are gender and age whereas the modifiable risk factors are body mass index, physical activity, etc.

Materials and methods: This is a prospective observational study, conducted among 100 patients (selected at conveniences) with knee osteoarthritis who were studied in the outpatient Orthopaedic Surgery, Samford Hospital, Ranchi, Jharkhand, India. An informed written consent was taken from all the participants. Patients were diagnosed using. The

American College of Rheumatology (ACR) classification criteria of osteoarthritis. All patients were treated with 3 monthly intra-articular injections of autologous platelet-rich plasma into the knee joint, under local anesthesia on an outpatient basis. All these cases were treated from April 2025 to March 2026.

Results: After 6 months, all patients were re-evaluated according to Age, Sex, BMI (Body mass index), Side involved, Severity (Grade) of osteoarthritis, Pre and post-PRP injection comparison of crepitus, local temperature, Joint line tenderness, Effusion, Range of motion, Visual Analog Scale for pain, International Knee Documentation Committee (IKDC) score (Table 2). The maximum and minimum age in this study was found to be 41 years and 70 years. The average age of the patients was calculated as the total age of patients/ no. of patients =52.68 yrs.

Conclusion: PRP procedure showed a higher degree of efficacy as well as significant findings of more and longer pain reduction, improved function, and patient satisfaction. This was particularly noticeable in the treatment of younger patients with less severe articular cartilage degeneration. All of the comparative studies suggest that PRP injections are a useful approach and an alternative in the treatment of OA. This minimally invasive procedure appears to be safe and effective. It could be utilized as a reasonable treatment option when other therapies fail or are inappropriate for the particular patient.

Key Words: Osteoarthritis, Platelet rich plasma, articular cartilage, Body mass index.

INTRODUCTION

Osteoarthritis is a degenerative, chronic disease that affects up to 80% of the population over 75 years of age. A recent report indicates that knee osteoarthritis is likely to become the fourth most crucial aetiology of physical limitation in women and the eighth most in men. In middle-aged persons, osteoarthritis may cause a major burden in lost time at work and early retirement. Non-modifiable risk factors for osteoarthritis are gender and age whereas the modifiable risk factors are body mass index, physical activity, etc.¹

Recent prospective studies have established that obesity is a primary risk factor for knee osteoarthritis. Increased loading of the knee joints can lead to cartilage breakdown and failure of components of structural support. Before 45 years of age, the prevalence of osteoarthritis in most joints is higher in men than in women. After about age 45 years, women are more often affected than men.²

In some studies, women have shown increased rates of cartilage loss and progression of knee cartilage defects than men.⁶ Analgesics, non-steroidal and steroidal anti-inflammatory drugs, glucosamine/chondroitin supplementation, physical therapy, and hyaluronic acid injections are useful in the treatment of osteoarthritis.³ However, most of them not addressing the pathology or have shown only minor benefits and significant side effects. New experimental studies have begun to target the biomechanical process of osteoarthritis with the focus on repairing cartilage or replacement.⁴ Autologous platelet-rich plasma therapy has got particular attention, in which high concentration of platelets achieved in a short volume of plasma after being placed in a centrifuge. Platelets play a vital part in tissue homeostasis.⁵

Our chief aim was to study the effects of intra-articular injections of Platelet-rich plasma in the management of knee joint osteoarthritis and to compare the results with standard studies and draw conclusion.

MATERIALS AND METHODS

This is a prospective observational study, conducted among 100 patients (selected at conveniences) with knee osteoarthritis who were studied in the outpatient Orthopaedic Surgery, Samford Hospital, Ranchi, Jharkhand, India. An informed written consent was taken from all the participants. Patients were diagnosed using The American College of Rheumatology (ACR) classification criteria of osteoarthritis. All

patients were treated with 3 monthly intra-articular injections of autologous platelet-rich plasma into the knee joint, under local anesthesia on an outpatient basis. All these cases were treated from April 2025 to March 2026.

A detailed history was taken. A preliminary general and physical examination were done. Build and nourishment noted. Systemic examination of the cardiovascular, respiratory, gastrointestinal and genitourinary examination was followed as routine. A detailed local examination of the knee joint was done. Data was entered in MS Excel 2007 and analysed. Preparation of autologous platelet-rich plasma (PRP)-30 ml of venous blood was taken from every patient and collected in sterile sodium citrated tubes. The tubes with citrated blood were centrifuged at 1800 rpm for 15 min to separate erythrocytes, and at 3500 rpm for 10 min to concentrate platelets. By this method, 3-5 ml of platelet-rich plasma were obtained and injected immediately without storage. It has been stated that using freshly harvested PRP might preserve all the platelet functions better.

PRP knee intra-articular injection technique- The injection was given in the supine position and with all aseptic precautions. The affected side was exposed up to the thigh and cleaned with betadine scrub (7.5%) and spirit. Then painted with 5% betadine solution and draped with linen towels. The knee joint was palpated, and good understanding of anatomical configuration was made. 2% Xylocaine injection was given in the skin and soft tissues of the lateral aspect of knee joint. The leg was held firm in neutral rotation,

and intra-articular injection of autologous platelet-rich plasma was given by the lateral approach with knee in complete extension using a 23-gauge needle. After injection, patients were instructed not to use the injected leg for 24 h, use ice packs over the injected joint and not to use NSAIDs during this period.

Inclusion Criteria:

Patients with history of chronic pain (of at least 4 months duration) or swelling of the knee, not responding to NSAIDs and/or physical therapy with radiographic findings of grade 1 (definite osteophyte, unimpaired joint space) and grade 2 (moderate diminution of joint space osteoarthritis of the knee joint) according to Kellgren-Lawrence scale were included in the study.

Exclusion Criteria:

Patients with diabetes, rheumatoid arthritis, major axial deviation (varus of more than 5 deg/valgus more than 5 deg), haematological diseases (coagulopathies), severe cardiovascular diseases, infections, immunosuppression, patients on therapy with anticoagulants-anti aggregants or nonsteroidal anti-inflammatory drugs within 5 days before blood donation, were excluded from the study.

Follow up Assessment after 6 months, all patients were re-evaluated by physical examination, assessment of visual analog scale for pain, international knee documentation committee (IKDC) score.

Statistical Analysis: Chi-square test was used to assess differences between quantitative and qualitative data at baseline and after 3 PRP injections. Spearman's correlation coefficient analysis was performed to identify factors associated with

better functional outcomes. The clinical features were evaluated using the chi-square test. The VAS scale and IKDC score were assessed using chi square test. A statistically significant cutoff value was set at $p < 0.05$.

RESULTS

After 6 months, all patients were re-evaluated according to Age, Sex, BMI (Body mass index), Side involved, Severity (Grade) of osteoarthritis, Pre and post-PRP injection comparison of crepitus, local temperature, Joint line tenderness, Effusion, Range of motion, Visual Analog Scale for pain, International Knee Documentation Committee (IKDC) score (Table 2). The maximum and minimum age in this study was found to be 41 years and 70 years. The

average age of the patients was calculated as the total age of patients/ no. Of patients = 52.68 yrs.

Out of 200 patients, 128 were females, and 112 were males. Out of 200 knee joints treated, 112 were the right side and 88 were the left side. 128 patients were found to be overweight, 48 were obese, and 24 were normal weight. The grading of osteoarthritis of the knee. Out of 200 study patients, 96 patients had grade 1 osteoarthritis, and 114 patients had grade 2 osteoarthritis. The clinical features were evaluated using the chi-square test. The VAS12 scale and IKDC13 score were assessed using the chi square test.

Kellgren-Lawrence Scale	No of patients	Percentage
Grade 1 (Doubtful)	96	48%
Grade 2 (Mild)	104	52%
Grade 3 (Moderate)	0	0%
Grade 4 (Severe)	0	0%

Table 1: Kellgren-Lawrence Grading of Patients with Primary Osteoarthritis

Clinical data	Baseline (number of patients out of 200)	After 6 Months Follow Up (No. of Patients out of 100)	P Value
Local rise of temp	20	0	<0.005
Tender joint line	132	60	<0.001
Crepitus	132	80	<0.001
Effusion	20	20	1
Limited range of movements	72	20	<0.002

Table 2: Clinical Evaluation of Patients with Primary Osteoarthritis after PRP Injection

DISCUSSION

Osteoarthritis is a major public health problem which causes pain and disability in one-third of all affected patients. The symptoms are often associated with notable functional impairment, as well as signs and symptoms of inflammation, including pain, stiffness, and loss of movement. Multiple factors are known to affect the progression of OA, including joint instability and/or malalignment, obesity, increasing age, associated intra-articular crystal deposition, muscle weakness, and peripheral neuropathy. Advances in molecular biology raise hopes that new therapeutic targets will be identified that will allow more than just symptomatic therapy. Joint replacement is still the unsurpassed therapy for advanced and incapacitating OA.⁶

However, with increasing appreciation of the contribution of all three joint compartments to disease progression, research in OA pathogenesis, biomarkers, and treatment has broadened immensely, and many new potential therapeutic targets have emerged over the past years. The growing interests in the use of PRP in OA treatment, which might provide cellular and humoral mediators to promote tissue healing and repair have gained momentum in the past few years and led to several studies.⁷

Autologous plasma is a biological therapy approach with the goal of delivering concentrated platelets to accelerate and support the healing of injuries to hard and soft tissue without exposing the patient to major risks. Growth factors, an essential part

of PRP, induce differentiation of mesenchymal stem cells into chondrocytes and thereby increase cell proliferation. They also suppress inflammatory mediators such as interleukin-1, encourage matrix deposition, and slow down catabolism.⁸

Hence, growth factors help stabilize cartilage homeostasis and possibly reverse articular degeneration. The use of autologous blood versus synthetic chemicals also eliminates the risk for allergic reaction or disease transfer in addition to limiting possible drug toxicity. The simple and efficient in-house preparation at the time of patient visit proves to be of advantage for the PRP procedure.

In our study 200 patients with Grade 1 or Grade 2 knee osteoarthritis treated with 3 monthly injections of platelet rich plasma and following conclusion made after six months of follow up. The average age documented was 52.68 years. Osteoarthritis of the knee was common in 5th and 6th decade of life, the commonest in between 51-and 55-years age group. In this study, 164 patients were found to be below the age of 60 years. Also, results were found to be better in the younger patients when compared to the older.⁹

In this study 128 patients (64%) were females, and 72 (36%) patients were male. The baseline visual analog score in female patients was 5.93 and 3.45 at 6 months, and that in males was 5.98 (Baseline) and 3.36 (at 6 Months) thus showing that there is no notable difference in response to treatment between males and females. The value of IKDC13 score in males was 38.75 (Baseline) and 76.08 (at 6 Months) and that in females was 38.42 (Baseline) and 76.14

(at 6 Months) therefore showing no significant difference in response to treatment in between males and females. Side effects related to the injection of platelet-rich plasma are considered uncommon and, when present, usually manifest in a mild and self-limited form. In our study, 24 patients experienced slight pain at the site of injection which lasted for one week and only one patient experienced marked pain. One patient had skin discoloration in the form of bruising. No cases suffered from infection or allergic reaction. Local symptoms are the most usual adverse events, ranging from pain at the injection site to signs of arthritis.¹⁰

CONCLUSION

PRP procedure showed a higher degree of efficacy as well as significant findings of more and longer pain reduction, improved function, and patient satisfaction. This was particularly noticeable in the treatment of younger patients with less severe articular cartilage degeneration. All of the comparative studies suggest that PRP injections are a useful approach and an alternative in the treatment of OA. This minimally invasive procedure appears to be safe and effective. It could be utilized as a reasonable treatment option when other therapies fail or are inappropriate for the particular patient.

REFERENCES

1. Karsdal MA, et al. Should subchondral bone turnover be targeted when treating osteoarthritis? *Osteoarthritis Cartilage*. 2008;16(6):638-46.
2. P.Lavage et al. Subchondral and trabecular bone metabolism regulation in canine experimental knee osteoarthritis. *Osteoarthritis and Cartilage* (2005) 13, 310-317.
3. Boyd SK, Muller R, Zernicke RF. Mechanical and architectural bone adaptation in early stage experimental osteoarthritis. *J Bone Miner Res*. 2002; 17(4):687-94.
4. Pietrzak WS, Eppley BL: Platelet rich plasma: Biology and new technology. *J Craniofac Surg* 2005; 16: 1043-54.
5. Eppley BL, Woodell JE, Higgins J: Platelet 13 quantify- cation and growth factor analysis from platelet-rich plasma: Implications for wound healing. *Plast Reconstr Surg* 2004; 114:1502-7.
6. Werner S, Grose R: Regulation of wound healing by growth factors and cytokines. *Physiol Rev* 2003; 83:835-70.
7. Jorge Chahla MD et al intra-articular cellular therapy for Osteo Arthritis and focal cartilage defects of the knee, *J Bone joint Surg A*. 2016;98:1511-21.
8. Lucarelli E, Fini M, Beccheroni A. Stromal stem cells and platelet-rich plasma improve bone allograft integration. *Clin Orthop* 2005;435:62-8.
9. Brian J. Cole, Shane T. Seroyer, Giuseppe Filardo, Sarvottam Bajaj and Lisa A. Fortier. Platelet-Rich Plasma: Where are we now and where are we going? *Sports health* 2010; 3: 203-210.
10. Iizaveta Kon, Bert Mandelbaum, Roberto Buda, Giuseppe Filardo, Marco Delcogliano, Antonio Timoncini, Pier Maria Fornasari, Sandro Giannini, Maurilio Marcacci. Platelet-Rich Plasma Intra- Articular Injection versus Hyaluronic

Acid Viscosupplementation as Treatments
for Cartilage Pathology: From Early
Degeneration to Osteoarthritis. Arthroscopy
2011; 11: 1490-1501.